Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE)
· seekingalpha.com
Biohaven (BHVN) stock dips as RBC downgrades the company to Sector Perform, citing its recent licensing deal worth up to $795M with SK Biopharma. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...